Literature DB >> 23656173

Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.

Chun-Chung Chen1, Sung-Tai Wei, Shiu-Chiu Tsaia, Xian-Xiu Chen, Der-Yang Cho.   

Abstract

In adults, mild traumatic brain injury (MTBI) frequently results in impairments of cognitive functions which would lead to psychological consequences in the future. Cerebrolysin is a nootropic drug, and can significantly improve cognitive function in patients with Alzheimer's disease and stroke. The purpose of this study was to investigate how Cerebrolysin therapy enhances cognitive recovery for mild traumatic brain injury patients using a double-blinded, placebo-controlled, randomized phase II pilot study. Patients having head injury within 24 h sent to our hospital were screened and recruited if patients were alert and conscious, and had intracranial contusion haemorrhage. From July 2009 to June 2010, totally, thirty-two patients were recruited in the double-blinded, placebo-controlled, and randomized study. Patients were randomized to receive Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60-min period for 5 days) or placebo (Group B, same dosage and administration of normal saline as Group A). The primary outcome measures were differences of cognitive function including Mini-Mental Status Examination (MMSE), and Cognitive Abilities Screening Instrument (CASI) scores between baseline and week 1, between baseline and week 4, and between baseline and week 12. Thirty-two patients completed the trial. For Group A, the CASI score difference between baseline and week 12 was 21.0 ± 20.4, a significantly greater change than that of Group B (7.6 ± 12.1) (p = 0.0461). Besides, drawing function (one of the domains of CASI; p = 0.0066) on week 4 and both drawing function (p = 0.0472) and long-term memory (one of the domains of CASI; p = 0.0256) on week 12 were also found to be significantly improved in the patients receiving Cerebrolysin treatment. Our results suggest that Cerebrolysin improves the cognitive function of the MTBI in patients at 3rd month after injury, especially for long-term memory and drawing function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23656173     DOI: 10.3109/02688697.2013.793287

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  17 in total

1.  Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.

Authors:  W Poon; C Matula; P E Vos; D F Muresanu; N von Steinbüchel; K von Wild; V Hömberg; E Wang; T M C Lee; S Strilciuc; J C Vester
Journal:  Neurol Sci       Date:  2019-09-07       Impact factor: 3.307

Review 2.  Nanoparticle-Based Therapeutics for Brain Injury.

Authors:  Vimala N Bharadwaj; Duong T Nguyen; Vikram D Kodibagkar; Sarah E Stabenfeldt
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

Review 3.  A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.

Authors:  Iman El Sayed; Adel Zaki; Akram M Fayed; Gihan M Shehata; Sherif Abdelmonem
Journal:  Neurosurg Rev       Date:  2016-08-18       Impact factor: 3.042

Review 4.  Strategies targeting endogenous neurogenic cell response to improve recovery following traumatic brain injury.

Authors:  Kaushal Patel; Dong Sun
Journal:  Brain Res       Date:  2016-02-08       Impact factor: 3.252

Review 5.  The Potential of Stem Cells in Treatment of Traumatic Brain Injury.

Authors:  Nicole M Weston; Dong Sun
Journal:  Curr Neurol Neurosci Rep       Date:  2018-01-25       Impact factor: 5.081

Review 6.  Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature.

Authors:  Shaun E Gruenbaum; Alexander Zlotnik; Benjamin F Gruenbaum; Denise Hersey; Federico Bilotta
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

7.  Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.

Authors:  Johannes C Vester; Anca D Buzoianu; Stefan I Florian; Volker Hömberg; Se-Hyuk Kim; Tatia M C Lee; Christian Matula; Wai Sang Poon; Dorel Sandesc; Nicole von Steinbüchel; Stefan Strilciuc; Pieter E Vos; Klaus von Wild; Dafin Muresanu
Journal:  Neurol Sci       Date:  2021-02-23       Impact factor: 3.307

8.  Cerebrolysin for vascular dementia.

Authors:  Shuhui Cui; Ning Chen; Mi Yang; Jian Guo; Muke Zhou; Cairong Zhu; Li He
Journal:  Cochrane Database Syst Rev       Date:  2019-11-11

Review 9.  Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy.

Authors:  Larry D Morries; Paolo Cassano; Theodore A Henderson
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-20       Impact factor: 2.570

Review 10.  A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.

Authors:  Rune A Kroken; Else-Marie Løberg; Tore Drønen; Renate Grüner; Kenneth Hugdahl; Kristiina Kompus; Silje Skrede; Erik Johnsen
Journal:  Front Psychiatry       Date:  2014-02-04       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.